Disc Medicine stock has its best day since 2022 as drug trial revives FDA approval hopes

Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its ...
InvestorsHub on MSN

Disc Medicine shares rise 60% after phase 3 bitopertin trial meets primary and secondary endpoints

Disc Medicine, Inc. (NASDAQ:IRON) shares increased 60% after the biotechnology company reported positive topline results from ...
BioPharma Dive

Disc’s once-spurned rare disease drug to get a second chance at approval

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...

What Could Disc Medicine (IRON) Reveal From Its Phase 3 APOLLO Trial?

Disc Medicine (NasdaqGM: IRON) plans to announce topline results from its APOLLO Phase 3 trial of bitopertin in EPP. The firm ...

Disc Medicine surges on late-stage trial win for lead asset developed with Roche

Disc Medicine (IRON) stock is set to jump after a Phase 3 trial win for lead asset developed with Roche (RHHBY) for ...

Disc Medicine’s Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission

Disc Medicine (NASDAQ:IRON) said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) ...
TipRanks

Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win

Disc Medicine stock gained on Monday following new clinical trial results that met primary and secondary endpoints.